Helios Technologies delivered its Q2 results on August 11 and took a modest step back — the stock slipped 2.8% on the day, landing at $81.06 — yet the Street's response has been to raise targets, not retreat.
The standout move came from JP Morgan, which lifted its price target from $100 to $110 this morning while maintaining its Overweight rating. That puts JPM's target nearly 36% above the current price, a gap wide enough to raise an eyebrow but one consistent with the broader pattern of upward revisions all year. Stifel and Keybanc both raised targets through July, to $93 and $95 respectively. The consensus mean now sits near $94.67, roughly 17% above where the stock is trading. The direction of travel is unambiguously bullish — no firm has cut a target or downgraded in the recent history. Bulls point to the company's transformation into a diversified subsystem provider, rising revenue and EBITDA guidance, and a balance sheet with low net leverage. Bears flag the usual industrial risks: weak construction markets, commodity exposure, and the potential for tariff pressure to bite margins if supply chain management stumbles.
The borrow market offers no additional tension here. Availability is essentially unlimited — the lending pool holds roughly 27.5 million shares available against a short position of under a million, pushing availability to the system cap. Cost to borrow is just 0.53%, up about 9% on the week but still trivially low in absolute terms. Short interest itself has crept up around 3.9% this week to 2.86% of free float, a low level that has been drifting modestly higher over the past month. Nothing in the lending data suggests any meaningful conviction among short sellers — this is a small, inexpensive position with acres of room for new entrants if sentiment sours.
Options positioning confirms the post-earnings recalibration. The put/call ratio sat at just 0.023 on August 11, still well below its 20-day average of 0.077 and close to the year's low. Pre-earnings, that collapse in the PCR flagged aggressive call-side positioning — the market was leaning hard into a positive print. The stock's 2.8% decline on results suggests the outcome was solid but not the blowout implied by options pricing. The PCR spike to 0.43 seen in early-to-mid July — which coincided with a brief tightening in availability and a short interest peak near 1.08 million shares — has fully unwound, and the market is back to a mildly bullish lean rather than an aggressive one.
Among peers, NPO added 1.2% on the day while CAT and GTES gave back 0.3% and closed flat respectively. PRLB gained 2.3% on the week, the strongest performer in the correlated group. HLIO's flat week — down just 0.5% — sits in the middle of the peer pack, neither leading nor lagging. With valuation multiples compressing slightly (PE has pulled back about 1.8 turns over the past week to just under 24x, EV/EBITDA near 15.5x), the stock is modestly cheaper than it was a week ago, even as analyst targets push higher.
The next data point to watch is whether the post-earnings target upgrades translate into institutional flows — BlackRock added roughly 150,000 shares through July, and Geode added over 100,000, suggesting passive and active alike were building ahead of the print.
See the live data behind this article on ORTEX.
Open HLIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
